Expression of MYCN in pediatric synovial sarcoma

Modern Pathology

Volumn 20, Issue 7, 2007, Pages 734-741

  Somers, Gino R ^a,b   Zielenska, Maria ^a,b   Abdullah, Shaker ^a   Sherman, Christopher ^c   Chan, Suzanne ^a   Thorner, Paul S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION 2; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; NESTIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; EPIGENETICS; EWING SARCOMA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NERVE SHEATH TUMOR; NEUROECTODERM TUMOR; ONCOGENE C MYB; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SENSITIVITY AND SPECIFICITY; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA;

ADOLESCENT; CELL CYCLE PROTEINS; CHILD; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, X; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFANT; INHIBITOR OF DIFFERENTIATION PROTEIN 2; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, SYNOVIAL; TRANSLOCATION, GENETIC;

EID: 34250643527     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800792     Document Type: Article

References (53)

1. Coffin CM, Dehner LP, O'Shea PA. Pediatric Soft Tissue Sarcomas: A Clinical, Pathological and Therapeutic Approach. Williams and Wilkins: Baltimore, 1997.
2. Fisher C, de Bruijn DRH, van Kessel AG. Synovial sarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours: Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2002, pp 200-204.
3. Schmidt D, Thum P, Harms D, et al. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer 1991;67:1667-1672.
4. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors, 4th edn. Mosby: St Louis, 2001, pp 1483-1509.
5. Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci USA 1987;84:1981-1985.
6. de Leeuw B, Berger W, Sinke RJ, et al. Identification of a yeast artificial chromosome (YAC) spanning the synovial sarcoma-specific t(X;18)(p11.2;q11.2) breakpoint. Genes Chromosomes Cancer 1993;6:182-189.
7. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994;7:502-508.
8. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995;14:2333-2340.
9. dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001;30:1-14.
10. Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999;91:974-975.
11. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-160.
12. Somers GR, Gupta AA, Doria AS, et al. Pediatric undifferentiated sarcoma of the soft tissues: a clinico-pathologic study. Pediatr Dev Pathol 2006;9:132-142.
13. Kempson RL, Fletcher CDM, Evans HL, et al. Tumors of the Soft Tissues, Vol. 30, 3rd edn. Armed Forces Institute of Pathology: Washington, DC, 2001.
14. Guillou L, Coindre J, Gallagher G, et al. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 2001;32:105-112.
15. Smith TA, Machen SK, Fisher C, et al. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol 1999;112:641-648.
16. O'Sullivan MJ, Kyriakos M, Zhu X, et al. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod Pathol 2000;13:1336-1346.
17. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
18. Manohar CF, Bray JA, Salwen HR, et al. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 2004;23:753-762.
19. Shohet JM, Hicks MJ, Plon SE, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62:1123-1128.
20. Lasorella A, Noseda M, Beyna M, et al. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000;407:592-598.
21. Thomas SK, Messam CA, Spengler BA, et al. Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 2004;279:27994-27999.
22. Driman D, Thorner PS, Greenberg ML, et al. MYCN gene amplification in rhabdomyosarcoma. Cancer 1994;73:2231-2237.
23. Garson JA, McIntyre PG, Kemshead JT. N-myc amplification in malignant astrocytoma. Lancet 1985;2:718-719.
24. Garson JA, Pemberton LF, Sheppard PW, et al. N-myc gene expression and oncoprotein characterisation in medulloblastoma. Br J Cancer 1989;59:889-894.
25. Squire J, Goddard AD, Canton M, et al. Tumour induction by the retinoblastoma mutation is independent of N-myc expression. Nature 1986;322:555-557.
26. Nisen PD, Zimmerman KA, Cotter SV, et al. Enhanced expression of the N-myc gene in Wilms' tumors. Cancer Res 1986;46:6217-6222.
27. Mizukami Y, Nonomura A, Takizawa T, et al. N-myc protein expression in human breast carcinoma: prognostic implications. Anticancer Res 1995;15:2899-2905.
28. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003;163:691-700.
29. Nagayama S, Katagiri T, Tsunoda T, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002;62:5859-5866.
30. Karube K, Nabeshima K, Ishiguro M, et al. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol 2006;59:160-165.
31. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-2591.
32. Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-8221.
33. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-7283.
34. Fligman I, Lonardo F, Jhanwar SC, et al. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol 1995;147:1592-1599.
35. Boerner S, Squire J, Thorner P, et al. Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction. Pediatr Pathol 1994;14:823-832.
36. Thorner PS, Ho M, Chilton-MacNeill S, et al. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Am J Surg Pathol 2006;30:635-642.
37. Sivak LE, Tai KF, Smith RS, et al. Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 1997;15:1937-1946.
38. Wada RK, Seeger RC, Brodeur GM, et al. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer 1993;72:3346-3354.
39. Cohn SL, Salwen H, Quasney MW, et al. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene 1990;5:1821-1827.
40. Nisen PD, Waber PG, Rich MA, et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-1637.
41. Slavc I, Ellenbogen R, Jung WH, et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990;50:1459-1463.
42. Bordow SB, Norris MD, Haber PS, et al. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-3294.
43. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
44. Maiorano D, Lemaitre JM, Mechali M. Stepwise regulated chromatin assembly of MCM2-7 proteins. J Biol Chem 2000;275:8426-8431.
45. Todorov IT, Werness BA, Wang HQ, et al. HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab Invest 1998;78:73-78.
46. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000;113:3897-3905.
47. Weggen S, Bayer TA, Koch A, et al. Characterization of neural cell lines derived from SV40 large T-induced primitive neuroectodermal tumors. Brain Pathol 1997;7:731-739.
48. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992;52:5334-5341.
49. Suzuki S, Adachi A, Hiraiwa A, et al. Cloning and characterization of human MCM7 promoter. Gene 1998;216:85-91.
50. Ohtani K, Iwanaga R, Nakamura M, et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 1999;18:2299-2309.
51. Aihara M, Sugawara K, Torii S, et al. Angiogenic endothelium-specific nestin expression is enhanced by the first intron of the nestin gene. Lab Invest 2004;84:1581-1592.
52. Lasorella A, Boldrini R, Dominici C, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002;62:301-306.
53. Vandesompele J, Edsjo A, De Preter K, et al. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 2003;22:456-460.